Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of long-acting compound in preparation of medicines

A compound and compound structural formula technology, applied to the application field in the preparation of medicines, can solve problems such as limiting the long-term effect of depression, and achieve the effect of long drug effect time

Active Publication Date: 2019-12-06
PEKING UNIV SHENZHEN GRADUATE SCHOOL
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] We found in animal experiments that (2R,6R; 2S,6S)-hydroxynorketamine (HNK) does not last long after administration, and loses its efficacy within 1 week, which seriously limits the treatment Desired long-term effect in depression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of long-acting compound in preparation of medicines
  • Application of long-acting compound in preparation of medicines
  • Application of long-acting compound in preparation of medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0096] Embodiment 1: compound preparation method

[0097]

[0098] Step 1: Starting from o-trifluoromethylbenzonitrile, according to the classic ketamine drug synthesis method Calvin Stevens method (preparation route as shown above) to obtain compound D 1 ;

[0099] Step 2: compound D 1 (2.57g, 10mmol) was added into 60ml THF, triethylamine (2.7mL, 20mmol) and Boc 2 O (3.32g, 15mmol), reflux 6h, cooling, spin dry, cross silica gel column to obtain compound E 1 3.25 g, 91% yield. 1 H NMR (300MHz, CDCl 3 ): δ7.80(d, J=8.1Hz, 1H), 7.66(d, J=7.8Hz, 1H), 7.49(t, J=7.5Hz, 1H), 7.22(t, J=7.5Hz, 1H ),5.76(s, 1H),4.30(s,1H),3.46-3.42(m,1H),2.45–2.36(m,1H),2.35-2.22(m,1H),1.76– 1.60(m,6H ),1.21(s,9H). 13 C NMR (75MHz, CDCl 3 ): δ208.9, 151.7, 149.0, 148.6, 136.1, 133.8, 132.6, 130.5, 129.0, 128.1, 128.0, 127.9, 127.8, 121.8, 121.7, 88.9, 80.8, 73.7, 40.0, 29.4, 28.2, 3

[0100] Step 3: Compound E 1 (2.14g, 6mmol) was added to dry 50ml THF, under argon protection, cooled to ...

Embodiment 2

[0103] Embodiment 2: activity test method:

[0104] 1. Forced swimming experiment

[0105] Transfer mice to the laboratory 1 h before the forced swim test (FST). Tests were performed under normal lighting conditions and monitored by a digital video camera. During the test, the mice were individually placed in transparent glass cylinders (28.5 cm high, 14 cm in diameter) containing 20 cm of water (23±1°C). On the first day, mice were trained for 6 min before being removed from the cylinder. On the second day, the mice were administered solvent (physiological saline) control group, HNK, CF3, and then tested their immobility time after 1 hour and 7 days, wherein the immobility time refers to passive floating without other actions. During the last 4 min of the entire 6-min swim test, immobility time was recorded by the Nodus system's EthoVision XT (Noldus, Netherlands) (Castagné et al., 2011, Hajmirzaian et al., 2014, Porsolt et al., 1977). After every two to three trials, the...

Embodiment 3

[0118] Embodiment 3: experimental result

[0119] 1. Depression-like behavior test results in mice:

[0120] Such as figure 1 Shown:

[0121] Depression-like behaviors were measured by the forced swim test. Mice received 10 mg of HNK, CF3 by intragastric administration, and immobility time was measured after 1 hour and 7 days. Percentage of immobility time is expressed as mean ± SEM *p<0.05, **p<0.0 compared to preactivity. N=8 per group Saline: saline mice; HNK: 2R,6R-hydroxynorchloramine-treated mice; CF3, CF3-treated mice.

[0122] 2. Differential protein analysis:

[0123] Such as figure 2 Shown:

[0124]A, with 0.833>Abundance Ratio>1.2 as the critical point, a Ratio value higher than 1.2 is defined as an up-regulated protein, and a Ratio value lower than 0.833 is defined as a down-regulated protein. Compared with the control group, there were 101 differentially expressed proteins in the CF3 treatment group, of which 39 differentially expressed proteins were co-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a compound with a long-acting treatment effect in preparation of medicines. The compound can be used for preparing medicines for depression resistance, anesthesia, analgesia, cognitive function improvement, lung protection, amyotrophic lateral sclerosis treatment and complex regional pain syndromes treatment.

Description

technical field [0001] The application relates to the field of medicine, in particular to the application of a compound for the treatment of depression, neurological and chronic pain, including Complex Regional Pain Syndrome (CRPS) in the preparation of medicine. Background technique [0002] Ketamine is a representative of phencyclidine intravenous anesthesia commonly used in clinical practice, and is one of the anesthetics with rapid development in clinical and basic research in recent years. In clinical practice, it is often used to meet the anesthesia needs of pediatrics, obstetrics, perioperative period, and patients with special diseases because of its characteristics of rapid induction, short action time, quick recovery, and less impact on the respiratory and circulatory systems. [0003] Ketamine was first synthesized in 1962, used in humans in 1965, and officially approved by the FDA for clinical use in 1970. Its typical "separation anesthesia" and short-term defin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/135A61K31/27A61P25/00A61P29/00A61P25/28A61P25/24A61P25/16A61P11/00A61P21/00A61P23/00C07C225/20
CPCA61P11/00A61P21/00A61P23/00A61P25/00A61P25/16A61P25/24A61P25/28A61P29/00C07B2200/07C07C225/20C07C2601/14Y02P20/55
Inventor 周强叶涛李书鹏
Owner PEKING UNIV SHENZHEN GRADUATE SCHOOL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com